Journal of Developmental Medicine(Electronic Version)  2025, Vol. 13 Issue (5): 385-390 DOI: 10.3969/j.issn.2095-5340.2025.05.010 |
|
|
|
|
|
|
| Progress in growth hormone therapy for small for gestational age infants |
| Wang Pingping, Zhang Yan, Yang Suhong
|
(Department of Endocrinology, Hangzhou Children's Hospital, Zhejiang, Hangzhou 310014, China)
|
|
|
|
Abstract 【Abstract】Children born small for gestational age infant (SGA) have a 5- to 7-fold higher risk of developing short stature in adulthood compared with those of normal birth weight. Additionally, their risk of developing metabolic diseases also increases. In recent years, recombinant human growth hormone (rhGH) has been used to increase the height of SGA children aged 2 to 4 years who exhibit insufficient catch-up growth. After 3 to 7 years of treatment, adult height can be increased by 6.9-12.6 cm. Overall, the safety profile of rhGH is favorable. Common adverse reactions include local pain and redness at the injection site, which mostly resolve spontaneously. A small proportion of children may experience transient hyperglycemia,
hypothyroidism, and other metabolic abnormalities.
|
|
Received: 30 July 2025
Published: 01 October 2025
|
|
|
|
|
|
